- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05052970
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
16. januar 2022 opdateret af: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
A Phase Ⅰ Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Studieoversigt
Status
Rekruttering
Betingelser
Detaljeret beskrivelse
This is a multicenter, open-label, phase I study aimed to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
In the study, 60 patients will be recruited into three dose groups.
All patients will receive the treatment for the planned 8 cycles(28 days per cycle)until disease progression or unacceptable drug-related adverse events
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
60
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Na An
- Telefonnummer: +86-010-63930582
- E-mail: anna@mail.ecspc.com
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina
- Rekruttering
- Beijing Chaoyang Hospital, Capital Medical University
-
Kontakt:
- Wenming Chen, Doctor
- Telefonnummer: 13910107759
- E-mail: 13910107759@163.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 75 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Patients fully understand and voluntarily participate in this study and sign informed consent;
- Aged 18-75 years, without gender limitation;
- Patients with relapsed or refractory multiple myeloma(confirmed by histologically or cytologically) who had received at least one prior line regular treatment;
- Patients have at least one of the following conditions:(1)Serum M protein≥10g/L;(2)Urine M protein≥200 mg/24h; (3)Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥100mg /L
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;
Laboratory tests meet the following conditions:
- Absolute neutrophil count (ANC) ≥1.5x10^9/L (No G-CSF treatment within 1 week prior to the laboratory test);
- Platelet count ≥ 75x10^9/L (No platelet transfusion within 1 week prior to the laboratory test);
- Total bilirubin ≤1.5upper limit of normal (ULN);
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN;
- Creatinine clearance(Ccr) ≥30mL/min.
- Females of childbearing potential must have a negative serum beta human chorionic gonadotrophin (β-hCG) pregnancy test result prior to enrollment and must agree to use an effective contraception method for the duration of the study treatment and 7 months after the last dose of study therapy.
Males patients and their partners must agree to use an effective contraceptive method for the duration of the study treatment and 4 months after the last dose of study therapy.
-
Exclusion Criteria:
- Patients with amyloidosis or central nervous system invasion or on dialysis treatment.
- Life expectancy < 3 months.
- History of allergy to mitoxantrone hydrochloride or liposomes;or previous treatment with adriamycin or other anthracyclines, with the total cumulative dose (doxorubicin equivalent) ≥350 mg/m^2.
- History of allergy (except local injection reaction) or intolerance to bortezomib;or one of the following conditions occurred with prior bortezomib regimens: no treatment response (not reach MR),disease progression within 6 months after the end of last dose.
- History of contraindications or intolerance to dexamethasone.
- Any anti-myeloma drug treatment or radiotherapy within 4 weeks prior to the first dose; or enrolled in any other clinical trials of anti-myeloma drug within 3 months prior to the first dose.
- History of autologous hematopoietic stem cell transplantation within 6 months prior to screening.
- History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
- Adverse events from the previous treatment have not resolved to ≤ Grade 1 (except for alopecia, hyperpigmentation).
- Patients with persistent Grade≥2 peripheral neuropathy or Grade 1 peripheral neuropathy with pain.
- Patients with impaired cardiac function or significant cardiac disease.
- HBsAg/HBcAb positive with HBV-DNA titer higher than the lower limit of the test value of the research center, or HCV antibody positive with HCV-RNA titer higher than the lower limit of the test value of the research center,or human immunodeficiency virus (HIV) antibody positive.
- Patients with obvious digestive system dysfunction, which may affect intake, transport and absorption of the study drug.
- Active bacterial, fungal or viral infections that require systemic treatment within 1 week prior to the first dose
- Patients underwent major surgery within 6 weeks prior to the first dose, or had a surgical schedule during the study period;
- History of additional malignant tumor within 5 years, except for locally curable cancer that has been cured.
- Other medical conditions that, in the judgment of the investigator, may affect the patient's participation in this study.
- Pregnant or breastfeeding women;
Not suitable for this study as decided by the investigator due to other reasons.
-
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: 12 mg/m ^ 2 dose group (ArmA)
Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle).
The dose of mitoxantrone hydrochloride liposome is 12 mg/m^2
|
Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
Andre navne:
Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
Andre navne:
Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
Andre navne:
|
Eksperimentel: 16 mg/m ^ 2 dose group (ArmB)
Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle).
The dose of mitoxantrone hydrochloride liposome is 16 mg/m^2
|
Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
Andre navne:
Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
Andre navne:
Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
Andre navne:
|
Eksperimentel: 20 mg/m ^ 2 dose group (ArmC)
Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle).
The dose of mitoxantrone hydrochloride liposome is 20 mg/m^2
|
Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
Andre navne:
Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
Andre navne:
Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Treatment-emergent adverse events (TEAEs)
Tidsramme: From the initiation of the first dose to 28 days after the last dose
|
To indentify the incidence of TEAEs
|
From the initiation of the first dose to 28 days after the last dose
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Objective response rate (ORR)
Tidsramme: Throughout the study treatment(Up to 32 weeks)
|
ORR is defined as the proportion of patients who have a best overall response of partial response (PR),very good partial response(VGPR), complete response (CR) or stringent complete response (sCR) as per International Myeloma Working Group (IMWG)
|
Throughout the study treatment(Up to 32 weeks)
|
Clinical Benefit Rate(CBR)
Tidsramme: Throughout the study treatment(Up to 32 weeks)
|
CBR is defined as the proportion of patients who have a best overall response of minimal response(MR),PR,VGPR,CR or sCR as per IMWG
|
Throughout the study treatment(Up to 32 weeks)
|
Disease control rate(DCR)
Tidsramme: Throughout the study treatment(Up to 32 weeks)
|
DCR is defined as the proportion of patients who have a best overall response of stable disease (SD),MR,PR,VGPR,CR or sCR as per IMWG
|
Throughout the study treatment(Up to 32 weeks)
|
Duration of response (DoR)
Tidsramme: Throughout the study completion.(An average of 12 months)
|
DoR is defined as the time from the first assessment of PR,VGPR,CR orsCR until the date of first occurrence of progressive disease (PD) as per IMWG
|
Throughout the study completion.(An average of 12 months)
|
Progression-free survival (PFS)
Tidsramme: Throughout the study completion.(An average of 12 months)
|
PFS is defined as the time from the date of first dose until the date of first documented PD as per IMWG or death from any cause, whichever occurs first
|
Throughout the study completion.(An average of 12 months)
|
Overall survival (OS)
Tidsramme: Throughout the study completion.(An average of 36 months)
|
OS is defined as the time from the date of first dose until the date of death from any cause
|
Throughout the study completion.(An average of 36 months)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Wenming Chen, Beijing Chaoyang Hospital affiliated to Capital Medical University
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
20. oktober 2021
Primær færdiggørelse (Forventet)
20. april 2023
Studieafslutning (Forventet)
20. juni 2024
Datoer for studieregistrering
Først indsendt
13. september 2021
Først indsendt, der opfyldte QC-kriterier
13. september 2021
Først opslået (Faktiske)
22. september 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. februar 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
16. januar 2022
Sidst verificeret
1. januar 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjerte-kar-sygdomme
- Karsygdomme
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Hæmatologiske sygdomme
- Hæmoragiske lidelser
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Myelomatose
- Neoplasmer, Plasmacelle
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Autonome agenter
- Agenter fra det perifere nervesystem
- Enzymhæmmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler
- Antineoplastiske midler
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Proteasehæmmere
- Topoisomerase II-hæmmere
- Topoisomerasehæmmere
- Dexamethason
- Dexamethasonacetat
- BB 1101
- Bortezomib
- Mitoxantron
Andre undersøgelses-id-numre
- HE071-CSP-023
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Recidiverende eller refraktært myelomatose
-
Nantes University HospitalTrukket tilbageCD22+ Relapsed/Refractory B-ALLFrankrig
Kliniske forsøg med Mitoxantrone Hydrochloride Liposome injection
-
Luye Pharma Group Ltd.AfsluttetAvanceret solid tumorKina
-
Huijing WuBeijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical...RekrutteringAngioimmunoblastisk T-celle lymfomKina
-
European Organisation for Research and Treatment...AfsluttetLivmoderhalskræftFrankrig, Spanien, Det Forenede Kongerige, Belgien, Israel, Schweiz, Italien
-
Second Affiliated Hospital of Soochow UniversityThe Affiliated Hospital of Xuzhou Medical UniversityRekrutteringRecidiverende/Refraktær MyelomKina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Suspenderet
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Ukendt
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.AfsluttetAvanceret gastrisk karcinomKina
-
Hui ZengCSPC Ouyi Pharmaceutical Co., Ltd.RekrutteringRecidiverende eller refraktær akut myeloid leukæmiKina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.AfsluttetRecidiverende eller refraktær akut myeloid leukæmi (AML)Kina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Ukendt